<DOC>
	<DOCNO>NCT01914159</DOCNO>
	<brief_summary>The Ranibizumab Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration ( RIP ) Study prospective , multicenter , uncontrolled , interventional phase 2 clinical trial investigates effect fix monthly intravitreal injection ranibizumab ( Lucentis , Novartis Pharma , Germany ) visual acuity retinal morphology study period 12 month 30 patient .</brief_summary>
	<brief_title>Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Diagnosis pigment epithelial tear secondary agerelated macular degeneration Written inform consent Time diagnosis 6 month study recruitment Ocular surgery study eye within 1 month study recruitment Extensive subretinal fibrosis retinal atrophy study eye Significant opacification optical medium study eye Uncontrolled glaucoma study eye Active ocular inflammation study eye Bestcorrected visual acuity contralateral eye 20/200 Concurrent ocular systemic therapy vascular endothelial growth factor ( VEGF ) inhibitory drug</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>